Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Prostate Cancer and Prostatic Diseases · Published 2026-01-08 · DOI 10.1038/s41391-025-01067-3

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1038/s41391-025-01067-3

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Robot-assisted MRI/US transperineal target prostate biopsy with Biobot Mona Lisa 2.0: first experience in Europe · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer · Prostate Cancer and Prostatic Diseases · 2025 · Same journal
• Persistence, progression, and PSA: what exactly does DEAR-EXT compare? · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Prostate biopsy - current discussions and future perspectives · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Counseling is counseling is counseling is counseling - The evolution of LUTS/BPO care · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Navigating drug–drug interactions with apalutamide · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Insights gained from single-cell transcriptomics on the cellular identity and plasticity of prostate epithelial cells · Prostate Cancer and Prostatic Diseases · 2026 · Same journal
• Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study · Prostate Cancer and Prostatic Diseases · 2025 · Same journal